Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

April 8, 2024

https://www.globenewswire.com/news-release/2024/04/08/2859185/33333/en/Coherus-Presents-Preclinical-Data-for-CHS-1000-a-Novel-Anti-ILT4-Antibody-at-the-2024-AACR-Annual-Meeting.html

– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion –
– Mechanism may enhance antitumor responses with immunotherapy –
– First novel immuno-oncology product candidate discovered and developed by Coherus –
– The CHS-1000 IND submission is planned for Q2 2024 –

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.